Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Participants entered the study taking tenofovir disoproxil fumarate, and some were switched to a regimen including tenofovir alafenamide.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
Newer drug classes are tied to a higher risk of weight gain, which is more likely to occur among Black women in particular.
However, serious kidney problems and bone fractures were rare among people taking either Descovy or Truvada for HIV prevention.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Evidence supports new PrEP option for gay men and trans women, but there’s no consensus for other groups.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
However, Tivicay plus Descovy was associated with greater weight gain, especially among women.
Descovy may offer protection against HIV faster and for longer than Truvada, but its higher cost may outweigh the apparent benefits.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
This will provide free PrEP to as many as 200,000 uninsured Americans until 2030.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.